Tiaprofeninsure

Bezeichnung:Tiaprofeninsure

CAS-Nr33005-95-7

Englisch Name:Tiaprofenic acid

CBNumberCB4875253

SummenformelC14H12O3S

Molgewicht260.31

MOL-Datei33005-95-7.mol

Synonyma

Tiaprofeninsure

Tiaprofeninsure physikalisch-chemischer Eigenschaften

Schmelzpunkt	96° (isopropyl ether)
Siedepunkt	373.57°C (rough estimate)
Dichte	1.2959 (rough estimate)
Brechungsindex	1.5050 (estimate)
storage temp.	2-8°C(protect from light)
Löslichkeit	Practically insoluble in water, freely soluble in acetone, in ethanol (96 per cent) and in methylene chloride.
pka	4.05±0.10(Predicted)
Aggregatzustand	Solid
Farbe	White to Almost white
maximale Wellenlänge (λmax)	314nm(Phosphate buffer sol.)(lit.)
Merck	14,9422

Sicherheit

RIDADR	UN 2811 6.1/PG III
RTECS-Nr.	XM7580000
HS Code	2934.99.3000
HazardClass	6.1
PackingGroup	III

Gefahreninformationscode (GHS)

Tiaprofenic acid Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
White or almost white, crystalline powder.
Originator
Surgam,Roussel,France,1975
Verwenden
Antiinflammatory;Cyclooxygenase inhibitor
Definition
ChEBI: An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group.
Manufacturing Process
A mixture of 10.3 g of thiophene-2α-methylacetic acid [prepared by process of Bercot-Vatteroni, et al., Bull. Soc. Chim. (1961) pp. 1820-21], 11.10 g of benzoyl chloride and a suspension of 23.73 g of aluminum chloride in 110 cc of chloroform was allowed to stand for 15 minutes and was then poured into a mixture of ice and hydrochloric acid. The chloroform phase was extracted with a 10% aqueous potassium carbonate solution and the aqueous alkaline phase was acidified with N hydrochloric acid and was then extracted with ether. The ether was evaporated off and the residue was crystallized from carbon tetrachloride to obtain a 54% yield of 5-benzoyl-thiophene-2α-methylacetic acid melting at 83°C to 85°C. The product occurred in the form of colorless crystals soluble in dilute alkaline solutions, alcohol and ether and insoluble in water.
Therapeutic Function
Antiinflammatory
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
Antibacterials: possibly increased risk of convulsions with quinolones.
Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban - avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with SSRIs and venlaflaxine.
Antidiabetic agents: effects of sulphonylureas enhanced.
Antiepileptics: possibly increased phenytoin concentration.
Antivirals: increased risk of haematological toxicity with zidovudine; concentration increased by ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.
Stoffwechsel
Sparingly metabolised in the liver to two inactive metabolites. Excretion of tiaprofenic acid and its metabolites are mainly in the urine in the form of acyl glucuronides; some is excreted in the bile.

Tiaprofenic acid Upstream-Materialien And Downstream Produkte

Tiaprofeninsure Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

33005-95-7, Tiaprofenic acid Verwandte Suche:

Send Inquriy